The strength of preclinical data presented here and the strong associations observed in the limited clinical trial data available make a compelling case for revisiting HER inhibitors in the ER+/HER2− breast cancer setting but this time in context of MutL status. This evidence concerns the gene ESR1 and breast carcinoma.